Table 2.
Meta-analysis of the association of HIF stabilizers with anemia due to chronic kidney disease
| Indicators | Group and subgroups | Number of studies |
Q test
|
Model selected | OR (95% CI) | P-value |
|---|---|---|---|---|---|---|
| P-value | ||||||
| Hb | Overall | 12 | <0.00001 | Random | 2.70 (1.79–3.61) | <0.00001 |
| NDD-CKD | 7 | <0.00001 | Random | 3.51 (2.20–4.82) | <0.00001 | |
| DD-CKD | 5 | <0.00001 | Random | 1.20 (−0.12 to 2.51) | 0.07 | |
| Ferritin | Overall | 11 | <0.00001 | Random | −0.65 (−1.12 to −0.18) | 0.006 |
| NDD-CKD | 6 | <0.00001 | Random | −1.12 (−1.92 to −0.32) | 0.006 | |
| DD-CKD | 5 | 0.05 | Random | −0.22 (−0.65 to 0.21) | 0.32 | |
| Hepcidin | Overall | 8 | <0.00001 | Random | −1.65 (−2.86 to −0.44) | 0.007 |
| NDD-CKD | 5 | <0.00001 | Random | −2.55 (−4.60 to −0.49) | 0.02 | |
| DD-CKD | 3 | 0.07 | Random | −14.39 (−50.70 to 21.91) | 0.44 | |
| TIBC | Overall | 11 | <0.00001 | Random | 1.64 (0.98–2.31) | <0.00001 |
| NDD-CKD | 6 | <0.00001 | Random | 2.05 (1.00–3.10) | 0.0001 | |
| DD-CKD | 5 | <0.00001 | Random | 1.30 (0.35–2.24) | 0.007 | |
| Reverse effect SAE | Overall | 5 | 0.71 | Fixed | 1.16 (0.81–1.67) | 0.42 |
| Overall | 4 | 0.72 | Fixed | 1.56 (0.91–2.66) | 0.11 |
Abbreviations: HIF, hypoxia-inducible factor; Hb, hemoglobin; TIBC, total iron-binding capacity; SAE, severe adverse event; NDD-CKD, non-dialysis-dependent chronic kidney disease; DD-CKD, dialysis-dependent chronic kidney disease.